Allos Therapeutics to Hold Post Advisory Committee Conference Call

Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the Company will hold a webcast conference call on Wednesday, September 2, 2009 to discuss the outcome of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee meeting for FOLOTYN™ (pralatrexate). FOLOTYN is the Company’s investigational selective antifolate that is currently being evaluated by the FDA for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Time: 5:30 pm ET / 4:30 pm CT / 3:30 pm MT / 2:30 pm PTDate: September 2, 2009Dial-in: 877-941-6009 (U.S. and Canada) or +1-480-629-9771 (international).Webcast: To access the live audio webcast or the subsequent archived recording, visit the “Investors - Presentations and Events” section of the Allos website at www.allos.com.

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call. Callers can access the replay by dialing 800-406-7325 (domestic) or +1-303-590-3030 (international). The passcode is 4151544#. The webcast will be recorded and available for replay on the Company's website until September 11, 2009.

About Allos Therapeutics

Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. The Company’s product candidate, FOLOTYN™ (pralatrexate), is a selective antifolate designed to accumulate preferentially in cancer cells. In May 2009, the FDA accepted the Company’s NDA for pralatrexate for the treatment of patients with relapsed or refractory PTCL for priority review and established a Prescription Drug User Fee Act date of September 24, 2009 for a decision regarding approval of the NDA. In addition, FOLOTYN is being evaluated in other tumor types, including solid tumors and a range of lymphoma sub-types. Allos retains exclusive worldwide rights to FOLOTYN for all indications. The Company is headquartered in Westminster, CO. For additional information, please visit www.allos.com.

The Allos logo is a trademark of Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024